Appointment of Non-Executive Director, Managing Director, Independent Non-Executive Director, Chairperson and CFO. Also for resignation of Non-Executive Director, Executive Director, Independent ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 1.6 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On January 19, 2026, the board approved a sweeping leadership change driven by a change in control through an open offer. Mr. Padmanaban Krishnamoorthy was appointed Non-Executive Director and Chairperson, along with his wife Ms. V. Varalakshmi as Non-Executive Director — signalling entry of a new promoter group. Ms. Poonam Chaturvedi was appointed Managing Director (1-year term) and Mr. Ravindranath Rajaram as new CFO. Two Independent Directors (Mr. Prasada Rao Kalluri, Mr. Mohammed Baba), one Whole Time Director (Mr. Balakrishna Koppula), one Non-Executive Director (Mrs. Vanitha Nagulavari), and the outgoing CFO (Mr. CHDVV Prasad Rao) all resigned. The company also proposed changing its name to CCME Global Limited / CCME International Limited / CCME Worldwide Limited, subject to MCA and shareholder approval. All key board committees (Audit, NRC, Stakeholder Relationship) were reconstituted.
Shareholders should view this as a complete change of control event — the old management team has exited and a new promoter family (Krishnamoorthy–Varalakshmi) is taking charge, including the proposed company rebrand to CCME Global Limited. This typically signals a strategic pivot or revival attempt, but near-term stock reaction may be volatile given the scale of disruption and pending shareholder/MCA approvals for name change.